Mean glycemic profile from enrolment till term.

<p>Mean glycemic profile from enrolment till term.</p

Metformin versus Insulin in the Management of Pre-Gestational Diabetes Mellitus in Pregnancy and Gestational Diabetes Mellitus at the Korle Bu Teaching Hospital: A Randomized Clinical Trial

<div><p>Objective</p><p>To determine if metformin monotherapy or metformin in combination with insulin is equally effective as insulin monotherapy at glycemic control in diabetes mellitus in pregnancy among Ghanaians.</p><p>Methods</p><p>This was a study involving 104 pregnant women with type 2 diabetes mellitus (T2DM) or gestational diabetes mellitus (GDM) at 20-30 weeks gestation. Participants were randomized into metformin and insulin treatment groups. Starting dose of metformin was 500 mg once a day and increased gradually over two (2) weeks, to meet glycemic targets. Insulin was added if targets could not be reached on metformin alone at maximum doses. Total daily dose of premixed insulin at initiation was calculated as 0.3 IU/kg body weight and titrated upwards to achieve glycemic control. Glycemic profile monitoring was done every two weeks.</p><p>Results</p><p>The two hour post prandial blood glucose (2HPG) levels were significantly lower in the metformin group than the insulin group (p= 0.004).</p><p>Conclusion</p><p>The findings of this study suggest that metformin monotherapy is effective in achieving glycemic targets in the management of diabetes in pregnancy. It is more effective than insulin in lowering the 2HPG level.</p><p>Trial Registration</p><p>Australian New Zealand Clinical Trials Registry (ANZCTR) <a href="http://www.ANZCTR.org.au/ACTRN12614000942651.aspx" target="_blank">ACTRN12614000942651</a></p></div

Mean 2HPG levels at baseline, one month from enrolment and at term for the two treatment groups.

<p>Mean 2HPG levels at baseline, one month from enrolment and at term for the two treatment groups.</p

Demographic characteristics of participants.

<p>*One patient each in the metformin group had malaria, multiple uterine fibroid, anemia as a co-morbid condition whiles one each for insulin had hepatitis B, G6PD and goiter</p><p>**One patient each in the metformin group had intrauterine fetal demise (IUFD), gestational diabetes, and gestational hypertension in their obstetric history whiles insulin group had one patient each with gestational diabetes, post-partum hemorrhage and IUFD.</p><p>Demographic characteristics of participants.</p

Flow diagram of participants from enrolment to term.

<p>Flow diagram of participants from enrolment to term.</p

Mean FBG levels at baseline, one month from enrolment and at term for the two treatment groups.

<p>Mean FBG levels at baseline, one month from enrolment and at term for the two treatment groups.</p